Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801223 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
A Phase 1 study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), sponsored by Innoviva Specialty Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06801223: Recruiting Phase 1 study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), sponsored by Innoviva Specialty Therapeutics.
NCT06801223 is a Phase 1 study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) that is actively recruiting participants, run by Innoviva Specialty Therapeutics. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801223, a Phase 1 study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), is actively recruiting participants, sponsored by Innoviva Specialty Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
Conditions Studied
Interventions
- DRUG Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)
- DRUG Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)
- DRUG Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- DRUG Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Study Locations (4)
California
- UCLA Medical Center - Los Angeles
- Rady Children's Hospital - San Diego
North Carolina
- ECU Brody School of Medicine - Greenville
Texas
- University of Texas Medical Branch at Galveston - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-10-30 |
| Est. Completion | 2028-05-20 |
| Phase | Phase 1 |
What NCT06801223 shows while recruiting
NCT06801223 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) appearing as the primary indexed condition, and to 4 interventions - of which Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) is the first listed.
NCT06801223 reports a single indexed study location in California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06801223 about?
NCT06801223 is a clinical study titled "A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection". The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-ca...
What is the current status of trial NCT06801223?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-10-30. Estimated completion is 2028-05-20.
What conditions does trial NCT06801223 study?
This clinical trial studies the following conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC).
What interventions are being tested in trial NCT06801223?
The interventions under investigation include: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) (DRUG), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) (DRUG), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) (DRUG), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours) (DRUG).
Who is sponsoring clinical trial NCT06801223?
This trial is sponsored by Innoviva Specialty Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801223 being conducted?
This trial has 4 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06801223's enrollment target sits among peer trials
48 1026th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI